Gloria Gonzalez-Aseguinolaza is the Director of the Gene Therapy for Rare Diseases program at CIMA, Universidad de Navarra, and Chief Scientific Officer (CSO) at Vivet Therapeutics.

Gloria has been working in gene therapy since the beginning of her scientific career. She completed her PhD in Madrid and her postdoctoral studies in New York, focusing on the development of genetic vaccines against parasites such as Leishmania and Malaria, which primarily affect developing countries. In 2001, she joined the Gene Therapy and Hepatology Department at the University of Navarra, where she led the gene therapy lab for liver diseases. From 2014 to 2020, she served as Director of the Gene Therapy and Regulation of Gene Expression Department at the Center for Applied Medical Research (CIMA) at the University of Navarra in Pamplona, Spain. She was appointed Deputy Director from 2019 to 2022 and served as Director of Research Innovation and Transfer from 2022 to 2023. Currently, she is the Director of the Gene Therapy for Rare Diseases program.

In 2016, Gloria co-founded Vivet Therapeutics, a European gene therapy company focused on developing therapies for liver diseases, along with Jean-Philippe Combal, where she serves part-time as CSO.

She has directly supervised 22 PhD students in gene therapy and has trained numerous undergraduate, graduate, and master's students in the field. Gloria has published over 160 papers in international scientific journals and contributed to the development of several gene therapy products. She has also served as President of the Spanish Society of Cell and Gene Therapy and is a board member of the European Society of Cell and Gene Therapy. In 2023, she received the Rosalind Franklin Foundation Award.